Jinghe Biotech Closes Nearly RMB 400 Million Series B Round, Continues to Lead Domestic Targeted Radiopharmaceutical Innovation

Bivision Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Bivision"), an innovative biopharma company focused on developing theranostic targeted radionuclide therapy (TRT), recently announced the completion of a nearly RMB 400 million Series B financing round. The round was co-led by Pudong Venture Capital, Zhangjiang Science and Technology Investment, and IDG Capital, with existing investor Gaorong Ventures continuing to increase its stake. Multiple well-known institutions also participated. Gaorong Ventures led Bivision's angel round in 2022 and has continued to add to its investment in subsequent rounds.

The proceeds from this round will be used for confirmatory clinical studies of the company's core pipeline, iteration of its technology platform, and full-speed advancement of differentiated innovative pipelines, while also planning the construction of a radiopharmaceutical R&D center.

Multiple Radiopharmaceutical Pipelines Advancing to Clinical Trials

Founded in 2021, Bivision is an innovative biopharmaceutical company based in China with a global outlook, specializing in targeted radionuclide therapy (TRT). The company is dedicated to building a diversified product pipeline through innovative molecular design and conjugation technologies, enabling precise tumor detection and targeted treatment.

To date, Bivision has established a complete radiopharmaceutical R&D chain and built proprietary technology platforms for targeted radiopharmaceutical development, rapidly establishing first-mover advantages and technical barriers in China's targeted radiopharmaceutical sector.

Targeting the massive unmet needs in oncology, Bivision has developed multiple differentiated pipelines. Among them, JH02, the company's first solid tumor pipeline and core program, has demonstrated significant advantages in safety, efficacy, and manufacturing simplicity. Compared with overseas counterparts, JH02 has the potential to achieve domestic substitution and break foreign monopolies, providing patients with more cost-effective treatment options.

Bivision's multi-tumor pipeline JH04 possesses theranostic potential across multiple tumor indications, capable of addressing broader unmet clinical needs and representing a key strategic deployment in Bivision's pan-cancer treatment efforts. JH04 has already initiated Phase I/II clinical studies, with promising preliminary investigator-initiated trial (IIT) data supporting the pipeline's development prospects. The company is also continuing to advance the R&D and clinical translation of other pipelines.

Innovation Leader in Radiopharmaceuticals

Dr. Haihua Yu, founder and CEO of Bivision, stated: "We are grateful to our new and existing shareholders for their strong recognition of and steadfast support for Bivision. Targeted radiopharmaceuticals stand at the forefront of global biopharmaceutical transformation. Since our founding, Bivision has adhered to the principle of 'patient needs first, pursuing excellence.' This infusion of capital will help us accelerate clinical translation — particularly in driving the global competitiveness of core pipelines such as JH02 and JH04 — and strive to bring China's original theranostic solutions to cancer patients worldwide as soon as possible."

A project lead at Gaorong Ventures commented: "Gaorong Ventures has invested in multiple rounds of Bivision, witnessing the team's successful advancement of several major radiopharmaceutical pipelines to pivotal registration clinical trials, demonstrating tremendous potential to become an innovation leader in the radiopharmaceutical field. We look forward to this financing round further accelerating Bivision's clinical trial progress and benefiting more patients at the earliest opportunity."

Going forward, Bivision will continue to deepen platform development, break technological monopolies, and drive the targeted radiopharmaceutical industry toward a new stage of high-quality development.